Retatrutide for Obesity and Knee Osteoarthritis
The TRIUMPH-4 Phase 3 trial, announced by Eli Lilly on December 11, 2025, is the first Phase 3 trial for retatrutide to report results. It was designed to evaluate retatrutide in adults with both obesity and knee osteoarthritis — two conditions that are deeply intertwined. The results were striking: weight loss of up to 28.7%, knee pain reduction of up to 75.8%, and approximately 1 in 7 participants on the 9mg dose becoming completely pain-free.
Osteoarthritis of the knee is the most common form of arthritis and a leading cause of disability worldwide. Obesity is one of its strongest modifiable risk factors — every pound of body weight translates to approximately 4 pounds of pressure on the knee joint. Weight loss has long been recommended as a first-line intervention, but achieving the magnitude of weight loss needed to meaningfully reduce symptoms has been difficult without surgery.
Retatrutide is an investigational drug that has not been approved by the FDA.
TRIUMPH-4 Trial Design
| Detail | Value |
|---|---|
| ClinicalTrials.gov | NCT05931367 |
| Participants | 445 |
| Duration | 68 weeks |
| Design | Randomized, double-blind, placebo-controlled |
| Doses | 9 mg and 12 mg (vs. placebo) |
| Population | Adults with obesity/overweight AND knee osteoarthritis |
| Co-primary endpoints | Percent change in body weight + WOMAC pain score |
Baseline characteristics
- Mean body weight: 112.7 kg
- Mean BMI: 40.4
- 84% had BMI of 35 or higher (Class 2 or 3 obesity)
- Mean baseline WOMAC pain score: 6.0 points (on a 0-10 scale)
The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is the standard validated instrument for measuring osteoarthritis symptoms. It assesses pain, stiffness, and physical function. The baseline pain score of 6.0 indicates moderate-to-severe knee pain.
Weight Loss Results
| Group | Weight Change (%) | Weight Change (kg) | Weight Change (lbs) |
|---|---|---|---|
| 9 mg | -26.4% | -29.1 kg | -64.2 lbs |
| 12 mg | -28.7% | -32.3 kg | -71.2 lbs |
| Placebo | -2.1% | — | — |
The 28.7% mean weight loss at 12mg over 68 weeks is the largest reported in any Phase 3 obesity trial to date. It confirms and extends the Phase 2 results (which showed up to 24.2% at 48 weeks), demonstrating that weight loss continues to progress between 48 and 68 weeks at the higher doses.
Knee Pain and Physical Function Results
WOMAC pain score
| Group | Pain Reduction (points) | Pain Reduction (%) | Completely Pain-Free |
|---|---|---|---|
| 9 mg | -4.5 | 75.8% | 14.1% |
| 12 mg | -4.4 | 74.3% | 12.0% |
| Placebo | -2.4 | 40.3% | 4.2% |
Both doses produced substantial pain improvement relative to placebo. Notably, the placebo group also showed meaningful improvement (40.3% pain reduction), which is common in osteoarthritis trials due to the natural fluctuation of symptoms and the placebo effect. However, the active treatment groups achieved roughly double the pain reduction of placebo.
Complete pain resolution
- 14.1% of 9mg participants and 12.0% of 12mg participants were completely free of knee pain at 68 weeks
- This compared to 4.2% on placebo
- Complete pain resolution is a high bar — it represents the elimination of all knee osteoarthritis pain, not merely an improvement
WOMAC physical function
| Group | Physical Function Improvement (points) |
|---|---|
| 9 mg | -4.1 |
| 12 mg | -4.2 |
| Placebo | -2.1 |
Physical function improvements paralleled the pain reductions, indicating that the benefits translated to real-world ability to perform daily activities — walking, climbing stairs, standing, and bending.
Cardiovascular and Metabolic Improvements
TRIUMPH-4 also measured cardiometabolic markers, all of which improved significantly in the retatrutide groups:
| Marker | Result at 12mg |
|---|---|
| Systolic blood pressure | -14.0 mmHg |
| Non-HDL cholesterol | Improved (specifics not disclosed) |
| hsCRP (inflammation) | Improved (specifics not disclosed) |
| Triglycerides | Improved (specifics not disclosed) |
The 14.0 mmHg reduction in systolic blood pressure is clinically meaningful — it approaches the effect size of some antihypertensive medications. The improvement in hsCRP (high-sensitivity C-reactive protein) is noteworthy because it is a marker of systemic inflammation, which is relevant to both cardiovascular disease and the inflammatory component of osteoarthritis.
How Weight Loss Affects Knee Osteoarthritis
The mechanism by which retatrutide improves knee osteoarthritis is primarily through weight loss. The relationship between obesity and knee osteoarthritis is both mechanical and metabolic:
Mechanical load
- Each pound of body weight translates to approximately 4 pounds of force on the knee joint during walking
- A person who loses 70 lbs (as achieved at the 12mg dose) reduces the load on their knee by approximately 280 lbs per step
- This reduction in mechanical stress decreases cartilage breakdown, reduces pain, and improves joint function
Systemic inflammation
- Obesity is associated with chronic low-grade inflammation, driven by adipose tissue (fat cells) secreting pro-inflammatory cytokines
- These inflammatory mediators contribute to cartilage degradation and joint pain beyond what mechanical loading alone explains
- Weight loss reduces adipose tissue-derived inflammation, as reflected in the hsCRP improvements seen in TRIUMPH-4
Why the 9mg and 12mg results were similar for pain
An interesting finding in TRIUMPH-4 was that the 9mg and 12mg doses produced very similar pain outcomes (75.8% vs. 74.3%) despite different weight loss (26.4% vs. 28.7%). This suggests that beyond a certain threshold of weight loss — perhaps around 25-26% — additional weight loss provides diminishing returns for joint pain relief. The mechanical offloading and anti-inflammatory effects may have reached a near-maximum benefit at the 9mg dose.
Safety and Adverse Events
The adverse event profile in TRIUMPH-4 was consistent with the GLP-1 drug class:
| Adverse Event | 9mg | 12mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Vomiting | 20.4% | 20.9% | 0.0% |
| Dysesthesia | 8.8% | 20.9% | 0.7% |
Discontinuation rates: 12.2% at 9mg, 18.2% at 12mg, and 4.0% for placebo. Eli Lilly noted that some discontinuations at higher doses were attributed to "perceived excessive weight loss" rather than intolerable side effects.
Dysesthesia (abnormal sensations such as tingling, burning, or numbness) was a new safety signal in this trial, particularly at the 12mg dose (20.9%). For detailed analysis of safety data, see Retatrutide Side Effects & Safety.
What This Means for Osteoarthritis Treatment
A potential new paradigm
Currently, the treatment options for obesity-related knee osteoarthritis are limited:
- Lifestyle modification — effective but difficult to sustain at the required magnitude
- Physical therapy — improves function and pain but does not address the root cause of excess weight
- NSAIDs and analgesics — symptom management only, with their own side effect risks
- Corticosteroid or hyaluronic acid injections — temporary relief
- Knee replacement surgery — effective but invasive, costly, and often deferred in younger patients
A drug that simultaneously addresses the root cause (obesity) and produces substantial symptom relief could reshape treatment algorithms for obesity-related osteoarthritis.
Regulatory implications
Eli Lilly has stated it plans to include the TRIUMPH-4 osteoarthritis data in its regulatory submissions. If approved, retatrutide could receive a specific indication for weight management in adults with obesity and knee osteoarthritis — similar to how Zepbound received an OSA indication.
Frequently Asked Questions
Does retatrutide treat osteoarthritis directly?
Retatrutide reduces knee osteoarthritis pain primarily through weight loss, which reduces mechanical load on the joint and systemic inflammation. It does not directly repair cartilage or reverse structural joint damage. However, by addressing the root cause (excess body weight), it produces substantial and clinically meaningful pain relief and functional improvement.
Is retatrutide better than knee replacement for osteoarthritis?
They address different aspects of the problem. Knee replacement surgically replaces damaged joint surfaces and can eliminate pain from structural joint damage. Retatrutide reduces the mechanical and inflammatory drivers of pain through weight loss. For patients whose osteoarthritis is primarily driven by obesity, significant weight loss may delay or eliminate the need for surgery. For patients with severe structural damage, joint replacement may still be necessary regardless of weight loss.
Can I take retatrutide for knee osteoarthritis now?
No. Retatrutide is not approved for any indication. If you have obesity-related knee osteoarthritis, talk to your doctor about currently available options, including tirzepatide (Zepbound/Mounjaro) or semaglutide (Wegovy/Ozempic) for weight management, combined with physical therapy and appropriate pain management.
Why were the 9mg and 12mg results similar for pain?
Despite the 12mg dose producing more weight loss (28.7% vs. 26.4%), both doses achieved nearly identical pain reduction (~75%). This likely reflects a ceiling effect — beyond approximately 25% weight loss, the additional mechanical offloading and inflammatory reduction produce diminishing returns for joint pain. This is actually encouraging, as it suggests the 9mg dose may be sufficient for this indication, potentially with a better tolerability profile.
Sources
- Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
- ClinicalTrials.gov: NCT05931367
- Messier, S.P., et al. (2004). Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis. Arthritis & Rheumatism.
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
If you have knee osteoarthritis, work with your orthopedist, rheumatologist, or primary care physician to develop a treatment plan using currently available therapies. Do not delay treatment while waiting for an unapproved drug.
This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.
Sources
- TRIUMPH-4 press release
Eli Lilly
- TRIUMPH-4 trial
ClinicalTrials.gov
Related reading
Retatrutide Clinical Trials & Results
Living tracker of all retatrutide trials — Phase 1 through the TRIUMPH Phase 3 program.
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.